Literature DB >> 12827058

Photodynamic therapy of corneal neovascularization with verteporfin.

Maurizio Fossarello1, Enrico Peiretti, Ignazio Zucca, Antonina Serra.   

Abstract

PURPOSE: To describe the effect of photodynamic therapy (PDT) using verteporfin (Visudyne) on corneal neovascularization (CNV) in two patients.
METHODS: Two patients with corneal neovascularization were treated with a nonthermal laser light at 689 nm delivered 15 min after an intravenous infusion of verteporfin. Postoperative outcome of neovascularization was followed clinically (inflammation, intraocular pressure, and visual acuity) and photographically [color photographs and corneal fluorescein and indocyanine green (ICG) angiography] for a minimum of 6 months.
RESULTS: Successful photothrombosis of corneal neovascularization was obtained immediately after treatment in the two patients, and regression was verified by corneal fluorescein and ICG angiography. In one case, partial vessel recanalization was observed after 1 month, and treatment was repeated, with complete regression of new vessels. No relevant side effects were observed in our cases.
CONCLUSIONS: PDT with verteporfin is an effective and safe procedure indicated for patients with corneal neovascularization; however, multiple sessions may be required.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12827058     DOI: 10.1097/00003226-200307000-00018

Source DB:  PubMed          Journal:  Cornea        ISSN: 0277-3740            Impact factor:   2.651


  8 in total

1.  Photodynamic therapy for corneal neovascularisation and lipid degeneration.

Authors:  B J Brooks; B K Ambati; D M Marcus; A Ratanasit
Journal:  Br J Ophthalmol       Date:  2004-06       Impact factor: 4.638

Review 2.  Corneal neovascularization and the utility of topical VEGF inhibition: ranibizumab (Lucentis) vs bevacizumab (Avastin).

Authors:  William Stevenson; Sheng-Fu Cheng; Mohammad H Dastjerdi; Giulio Ferrari; Reza Dana
Journal:  Ocul Surf       Date:  2012-01-25       Impact factor: 5.033

3.  Attenuation of corneal neovascularization by topical low-molecular-weight heparin-taurocholate 7 without bleeding complication.

Authors:  Jae Yong Kim; Soo Yeon Kim; Mi Hyun Cheon; Eun-Soon Kim; In Seok Song; Myoung Joon Kim; Hungwon Tchah
Journal:  Int J Ophthalmol       Date:  2016-09-18       Impact factor: 1.779

4.  Regression of aggressive corneal vascularization after photodynamic therapy, subconjunctival Avastin injections and topical cyclosporin-A 1% drops: A case report.

Authors:  Omar M Kirat; Hassan A Al-Dhibi
Journal:  Saudi J Ophthalmol       Date:  2010-05-27

Review 5.  Corneal transparency: genesis, maintenance and dysfunction.

Authors:  Yureeda Qazi; Gilbert Wong; Bryan Monson; Jack Stringham; Balamurali K Ambati
Journal:  Brain Res Bull       Date:  2009-05-27       Impact factor: 4.077

6.  KH906, a recombinant human VEGF receptor fusion protein, is a new effective topical treatment for corneal neovascularization.

Authors:  Tao Li; Andina Hu; Shiqing Li; Yan Luo; Juan Huang; Honghua Yu; Wei Ma; Jianying Pan; Qi Zhong; Jin Yang; Jianming Wu; Shibo Tang
Journal:  Mol Vis       Date:  2011-03-25       Impact factor: 2.367

7.  Photodynamic therapy with verteporfin for corneal neovascularization.

Authors:  Abdullah A Al-Torbak
Journal:  Middle East Afr J Ophthalmol       Date:  2012 Apr-Jun

8.  The inhibitory effect of different concentrations of KH902 eye drops on corneal neovascularization induced by alkali burn.

Authors:  Yan Wu; Chunyan Xue; Yan Lu; Zhenping Huang
Journal:  Indian J Ophthalmol       Date:  2017-11       Impact factor: 1.848

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.